On August 6, Novo-Nordisk A/S rose 3.12% in pre-market trading, trading at $45.97/share, with turnover of $4.08 million. The rebound follows the previous session's sharp selloff of nearly 6% despite a strong Q2 earnings beat, as investors reassess the company's core GLP-1 business fundamentals.

On the news front, Novo-Nordisk won a preliminary injunction from the District Court of The Hague against Ceban Ziekenhuisfarmacie B.V., ordering the Dutch company to immediately stop selling a compounded semaglutide nasal spray that infringed Novo's supplementary protection certificate. Additionally, CEO Mike Doustdar stated the company sees no need for transformative M&A, signaling confidence in its internal pipeline. These developments come on the heels of Q2 results where adjusted EPS of $0.96 beat consensus of $0.81 by 18.5%, and sales of $12.21 billion topped the $11.35 billion estimate, prompting an upward revision to full-year sales and operating profit guidance driven by GLP-1 product strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)